{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"520","value":"229"},{"groupId":"OG001","spread":"65.8","value":"464"},{"groupId":"OG002","spread":"224","value":"484"},{"groupId":"OG003","spread":"93.6","value":"2067"},{"groupId":"OG004","spread":"31.9","value":"1954"},{"groupId":"OG005","spread":"66.6","value":"3440"},{"groupId":"OG006","spread":"53.5","value":"5848"},{"groupId":"OG007","spread":"61.9","value":"5571"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"564"},{"groupId":"OG009","spread":"53.6","value":"655"},{"groupId":"OG010","spread":"47.0","value":"1124"},{"groupId":"OG011","spread":"35.6","value":"1737"},{"groupId":"OG012","spread":"428","value":"814"},{"groupId":"OG013","spread":"33.3","value":"3863"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"598","value":"294"},{"groupId":"OG001","spread":"113","value":"636"},{"groupId":"OG002","spread":"222","value":"647"},{"groupId":"OG003","spread":"67.7","value":"2857"},{"groupId":"OG004","spread":"37.0","value":"3025"},{"groupId":"OG005","spread":"67.4","value":"4938"},{"groupId":"OG006","spread":"74.6","value":"8812"},{"groupId":"OG007","spread":"48.4","value":"9078"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"955"},{"groupId":"OG009","spread":"73.7","value":"965"},{"groupId":"OG010","spread":"52.7","value":"1508"},{"groupId":"OG011","spread":"42.1","value":"2470"},{"groupId":"OG012","spread":"557","value":"1172"},{"groupId":"OG013","spread":"24.0","value":"7274"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"title":"Total Antibody Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG004","spread":"322","value":"0.00100"},{"groupId":"OG005","spread":"751","value":"0.00600"},{"groupId":"OG006","spread":"298","value":"0.00300"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG007","spread":"NA","value":"0.00100"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG010","spread":"NA","value":"0.0110"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG011","spread":"NA","value":"0.00100"},{"groupId":"OG012","spread":"57.2","value":"0.00100"},{"groupId":"OG013","spread":"228","value":"0.00200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Unconjugated SG3199 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.3","value":"588"},{"groupId":"OG001","spread":"92.4","value":"676"},{"groupId":"OG002","spread":"95.5","value":"898"},{"groupId":"OG003","spread":"126","value":"2386"},{"groupId":"OG004","spread":"44.0","value":"2668"},{"groupId":"OG005","spread":"101","value":"4025"},{"groupId":"OG006","spread":"22.0","value":"8305"},{"groupId":"OG007","spread":"46.1","value":"6599"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"2421"},{"groupId":"OG009","spread":"37.6","value":"825"},{"groupId":"OG010","spread":"57.0","value":"1392"},{"groupId":"OG011","spread":"84.6","value":"1716"},{"groupId":"OG012","spread":"145","value":"1386"},{"groupId":"OG013","spread":"66.2","value":"4535"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.6","value":"769"},{"groupId":"OG001","spread":"107","value":"880"},{"groupId":"OG002","spread":"105","value":"1060"},{"groupId":"OG003","spread":"116","value":"3740"},{"groupId":"OG004","spread":"35.8","value":"4910"},{"groupId":"OG005","spread":"72.2","value":"5815"},{"groupId":"OG006","spread":"18.8","value":"11879"},{"groupId":"OG007","spread":"48.0","value":"9027"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"4796"},{"groupId":"OG009","spread":"47.5","value":"1128"},{"groupId":"OG010","spread":"57.3","value":"1653"},{"groupId":"OG011","spread":"74.9","value":"2609"},{"groupId":"OG012","spread":"41.3","value":"3203"},{"groupId":"OG013","spread":"44.1","value":"7077"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Total Antibody Cycle 2"},{"categories":[{"measurements":[{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG003","spread":"NA","value":"0.00100"},{"groupId":"OG004","spread":"1630","value":"0.00400"},{"groupId":"OG005","spread":"14068","value":"0.00200"},{"groupId":"OG006","spread":"3.13","value":"0.0320"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG010","spread":"NA","value":"0.00600"},{"groupId":"OG011","spread":"293","value":"0.00300"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG012","spread":"NA","value":"0.00300"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG013","spread":"NA","value":"0.00100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"}],"units":"Participants"}],"title":"Unconjugated SG3199 Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"description":"PK profile included AUC0-last of ADCT-301 in Serum total antibody, PBD-conjugated antibody, and unconjugated warhead SG3199. For participants treated with ADCT-301 in combination with pembrolizumab, the collection of PK data was stopped upon consultation with the Sponsor if ADCT-301 administration was discontinued and pembrolizumab continues.\n\nUpon consultation with the Sponsor, no further PK samples were collected, ADCT-301 was permanently discontinued and pembrolizumab continues as single agent.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"ADCT-301 Monotherapy 20 µg/kg"},{"description":"Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"ADCT-301 Monotherapy 30 µg/kg"},{"description":"Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"ADCT-301 Monotherapy 45 µg/kg"},{"description":"Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"ADCT-301 Monotherapy 60 µg/kg"},{"description":"Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"ADCT-301 Monotherapy 80 µg/kg"},{"description":"Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"ADCT-301 Monotherapy 100 µg/kg"},{"description":"Participants received 125 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG006","title":"ADCT-301 Monotherapy 125 µg/kg"},{"description":"Participants received 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG007","title":"ADCT-301 Monotherapy 150 µg/kg"},{"description":"Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG008","title":"ADCT-301 Combination Therapy 20 µg/kg + Pemb"},{"description":"Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG009","title":"ADCT-301 Combination Therapy 30 µg/kg + Pemb"},{"description":"Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG010","title":"ADCT-301 Combination Therapy 45 µg/kg + Pemb"},{"description":"Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG011","title":"ADCT-301 Combination Therapy 60 µg/kg + Pemb"},{"description":"Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG012","title":"ADCT-301 Combination Therapy 80 µg/kg + Pemb"},{"description":"Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG013","title":"ADCT-301 Combination Therapy 100 µg/kg + Pemb"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Analysis Set: The PK analysis set consisted of all participants who received study drug and had at least 1 pre-C1D1 and 1 post-dose valid assessment.\n\nThe overall number of participants analyzed represents the number of participants with available PK data at any timepoint.\n\nIncludes participants with available data at each timepoint.","reportingStatus":"POSTED","timeFrame":"C1D1, from Pre-dose to 4 hr, 96 hr, 168 hr and 336 hr post dose; C2D1, from Pre-dose to 4 hr, 48 hr, 96 hr, 168 hr and 336 hr post dose","title":"Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of ADCT-301 in Serum Total Antibody, PBD-conjugated Antibody, and Unconjugated Warhead SG3199","type":"SECONDARY","unitOfMeasure":"day*ng/mL"}